New hope for multiple cancers with pembrolizumab combination therapies

The combination of pembrolizumab and the checkpoint inhibitor known as epacadostat is leading to promising responses and is generally well tolerated in patients with triple-negative breast cancer, non-small cell lung cancer, squamous cell cancer of the head and neck, and several other cancers, according to researchers. (Mehr in: Cancer News — ScienceDaily)